Albert David Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Albert David Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Albert David was listed on the National Stock Exchange (NSE) on 14-Jun-2016. Albert David share has its face value of 10 per share, and its NSE symbol is ALBERTDAVD. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Albert David Q4 Results 2026 Preview

• Albert David Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 11-15% YoY increase compared to the same quarter last year.
• Profit After Tax, or PAT, is projected to rise 12-17% YoY.
• EBITDA to rise 11-16%.
• Albert David is expected to show Moderate Growth Expected in its revenue. 

Click and Sign Up to Get Live Updates on Q4 Results

Albert David Share Performance

• Over the past six months, Albert David share price has Up by 22% to 670.6.
• Moreover, over the past year, the stock has Up by 38%
• Despite this weak short-term performance, Albert David stock has delivered a financially sound 190% return over the past 5 years.
• As of today, 20-03-2026, the Albert David share price is trading at 670.6 per share.

Key Factors to Watch for Albert David Q4 Results FY26

• Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
• Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
• Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
• Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
• Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Albert David

Albert David is an Indian pharmaceutical company specializing in manufacturing and marketing pharmaceuticals, intravenous fluids, and nutraceuticals. It serves both domestic and international markets, focusing on therapeutic segments like anti-infectives, vitamins, and critical care solutions.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Albert David is gear up to announce its Q4 FY26 results. Analysts expect 11-15% revenue growth, a 12-17% rise in PAT, and a 11-16% rise in EBITDA. Albert David focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Albert David Q4 results FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Siemens Energy Q4 FY26 Earnings Preview Expectations Outlook

Entertainment Network Q4 FY26 Earnings Preview Outlook

Energy Development Q4 FY26 Earnings Preview Outlook

Endurance Technologies Q4 FY26 Earnings Preview Expectations Outlook

eMudhra Q4 FY26 Earnings Preview Expectations Outlook